All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Pretreatment with Prasugrel in Non-ST-Segment Elevation Acute Coronary Syndromes

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F13%3A43907678" target="_blank" >RIV/00216208:11120/13:43907678 - isvavai.cz</a>

  • Alternative codes found

    RIV/00064173:_____/13:#0000364 RIV/00023001:_____/13:00058799

  • Result on the web

    <a href="http://dx.doi.org/10.1056/NEJMoa1308075" target="_blank" >http://dx.doi.org/10.1056/NEJMoa1308075</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1056/NEJMoa1308075" target="_blank" >10.1056/NEJMoa1308075</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Pretreatment with Prasugrel in Non-ST-Segment Elevation Acute Coronary Syndromes

  • Original language description

    Although P2Y(12) antagonists are effective in patients with non-ST-segment elevation (NSTE) acute coronary syndromes. We evaluated the effect of administering the P2Y(12) antagonist prasugrel at the time of diagnosis versus administering it after the coronary angiography if percutaneous coronary intervention (PCI) was indicated. We enrolled 4033 patients with NSTE acute coronary syndromes and a positive troponin level who were scheduled to undergo coronary angiography within 2 to 48 hours after randomization. Patients were randomly assigned to receive prasugrel before the angiography (pretreatment group) or placebo (control group). When PCI was indicated, an additional 30 mg of prasugrel was given in the pretreatment group at the time of PCI and 60 mgof prasugrel was given in the control group. The rate of the primary efficacy end point, a composite of death from cardiovascular causes, myocardial infarction, stroke, urgent revascularization, or glycoprotein IIb/IIIa inhibitor rescue t

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FA - Cardiovascular diseases including cardio-surgery

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    N - Vyzkumna aktivita podporovana z neverejnych zdroju

Others

  • Publication year

    2013

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    New England Journal of Medicine

  • ISSN

    0028-4793

  • e-ISSN

  • Volume of the periodical

    369

  • Issue of the periodical within the volume

    11

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    12

  • Pages from-to

    999-1010

  • UT code for WoS article

    000324304200009

  • EID of the result in the Scopus database